高危肾细胞癌的辅助治疗：离开沙漠？
Adjuvant Treatment of High-risk Renal Cell Carcinoma: Leaving the Desert?
机构信息
Department of Urology, Ernst-Moritz-Arndt-University, Greifswald, Germany.
Department of Urology, Eberhard Karls University, Tübingen, Germany.
出版信息
Eur Urol. 2017 May;71(5):695-696. doi: 10.1016/j.eururo.2016.10.023. Epub 2016 Oct 27.
PMID:28085669
Abstract
In a recent trial, adjuvant treatment with sunitinib significantly prolonged disease-free survival compared to placebo. This positive result is muted by the rate of side effects and overtreatment, raising the question of proper patient and agent selection in the adjuvant setting.
摘要
在最近的一项试验中，与安慰剂相比，舒尼替尼的辅助治疗显著延长了无病生存期。但副作用发生率和过度治疗使这一积极结果黯然失色，这引发了在辅助治疗环境中适当选择患者和药物的问题。
Zotero 插件